Share
The global US Antisense Oligonucleotide (ASO) Drugs market size was valued at approximately USD 2.5 billion in 2025 and is projected to reach USD 7.8 billion by 2035, growing at a CAGR of 11.5% during the forecast period. Antisense oligonucleotides are short, synthetic single strands of DNA or RNA that can alter gene expression. The market primarily comprises innovations targeting rare genetic disorders, cancer, and neurodegenerative diseases, where traditional pharmacology faces limitations.
The ASO drugs market represents a cutting-edge development in personalized medicine, offering tailored therapies that precisely target genetic sequences. Products in this market include clinically developed ASO compounds targeting various precise genetic conditions. The market ecosystem involves biotechnology and pharmaceutical companies, regulatory bodies, genetic researchers, health professionals, and patient advocacy groups. Major end-use applications encompass treatment of genetic disorders, cancer therapies, and other chronic diseases.
This market has evolved substantially from basic research phases to commercial product offerings, transitioning from a niche status to a more inclusive part of advanced therapeutic modalities. The strategic importance of this market is underscored by ongoing collaborations between biopharmaceutical firms and genomics research institutions aimed at expanding ASO applications and improving therapeutic outcomes.
To get full access to our Market Insights, you need a Professional Account or a Business Suite.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Our customers work more efficiently and benefit from
